Enterprise Value to EBITDA Multiple ratio Analysis of Ligand Pharmaceuticals Incorp. - Deep Dive


Latest FY EV to EBITDA
Period Ending - Dec-23

25.58


Very Poor EV to EBITDA
Period Ending - Dec-22
15.22

Not Good EV to EBITDA
Growth
68.04 %
Trailing Twelve Months EV to EBITDA
Period Ending - Dec-23

-206.46


Very Poor EV to EBITDA
EV to EBITDA Analysis of Ligand Pharmaceuticals Incorp.
Enterprise Value to EBITDA of Ligand Pharmaceuticals Incorp. with value of 25.58 implies that the company is overvalued.
EV to EBITDA Ratio of LGND rose handsomely by 68.04 % this year.
EV to EBITDA Ratio with value of 55.64 was highest in Year Dec-20 in last Five Years.
EV to EBITDA Ratio with value of 3.56 was lowest in Year Dec-19 in last Five Years.
Latest EV to EBITDA Ratio with value of 25.58 is Greater than Average EV to EBITDA of 23.75 in last five years.
Other EV to EBITDA Related Info of LGND that may interest you.
Ligand Pharmaceuticals Incorp. Overview
CodePricePrevious PricePrice ChangeSector
LGND80.6480.06 0.724 % Biotechnology
Fundamental AnalysisTechnical Analysis
Defination of Enterprise Value to EBITDA Multiple
Enterprise Value-to-EBITDA Ratio is used to compare a company's Enterprise Value to its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization). It is useful to determine the value of a company, whether it is undervalued or overvalued.    more ..
Enterprise Value to EBITDA Multiple Formula
EV to EBITDA Related Ratios
EBITDAMarginEVToRevenuePriceToEarningRatio
Tsr Value Index
Poor Value Stock
FY - Historical Enterprise Value to EBITDA Multiple of Ligand Pharmaceuticals Incorp.
PeriodDec-23Dec-22Dec-21Dec-20Dec-19Dec-18Dec-17
EV to EBITDA25.5815.2218.7555.643.5615.3647.26
Change68.04 %-18.81 %-66.30 %1461.11 %-76.80 %-67.49 %-67.63 %
You are view first 7 Records. Log in to view all 30 in Premium view
FY Chart of Enterprise Value to EBITDA Multiple of Ligand Pharmaceuticals Incorp.


Note : All Data Generated at the End of Trading Hours (EOD Data)